Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Ra Pharmaceuticals, Inc.

Home Clinical Trial Sponsors and OrganizationsRa Pharmaceuticals, Inc.

Ra Pharmaceuticals, Inc.

ACTIVE

87 Cambridgepark Dr, 马萨诸塞州米德尔塞克斯县, Massachusetts, United Stateswww.rapharma.comSubsidiary89 employeesEstablished: 2008-01-01

Also known as:

ra pharmaceuticals

Part of UCB Holdings, Inc.

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

Clinical Trials

26

20 active

Approvals

0

Total approvals

Agencies

0

Regulatory bodies

Founded

2008

Overview

Trial Phase Distribution

Phase

Trials

Share

Phase 1

20

76.9%

Phase 2

5

19.2%

Phase 3

1

3.9%

Trial Status Distribution

Active, not recruiting

20

76.9%

Completed

4

15.4%

Terminated

2

7.7%

Clinical Trials

Trials sponsored by this organization (26)

A Study to Confirm the Safety, Tolerability, and Efficacy of Zilucoplan in Patients with Generalized Myasthenia Gravis

Active, not recruiting

Jan 2021130 participants

Open-Label Extension Study of Zilucoplan in Subjects with Generalized Myasthenia Gravis

Active, not recruiting

Jan 2021200 participants

A Study to Evaluate the Safety, Tolerability, and Efficacy of Zilucoplan in Subjects with Immune-Mediated Necrotizing Myopathy

Active, not recruiting

Jan 202024 participants

Open-Label Extension Study of Zilucoplan in Subjects with Generalized Myasthenia Gravis

Active, not recruiting

Jan 2020200 participants

A Study to Confirm the Safety, Tolerability, and Efficacy of Zilucoplan in Patients with Generalized Myasthenia Gravis

Active, not recruiting

Nov 2019130 participants

Safety and Efficacy Study of Zilucoplan in Subjects With Immune-Mediated Necrotizing Myopathy

Nov 201927 participants

Open-Label Extension Study of Zilucoplan in Subjects with Generalized Myasthenia Gravis

Active, not recruiting

Nov 2019200 participants

A Study to Confirm the Safety, Tolerability, and Efficacy of Zilucoplan in Patients with Generalized Myasthenia Gravis

Active, not recruiting

Nov 2019130 participants

Page 1 of 4

Approvals

No approval data available

News

GlycoEra Appoints Petra Duda as Chief Medical Officer to Lead Precision Protein Degrader Pipeline

- GlycoEra AG has appointed Petra Duda, M.D., Ph.D., as Chief Medical Officer to lead clinical development of its precision immune degrader pipeline. - Dr. Duda brings over 20 years of experience in clinical development and regulatory strategy, with expertise in immune-mediated and rare diseases. - She will oversee advancement of GlycoEra's lead IgG4 degrader program GE8820 for autoimmune diseases including pemphigus, MuSK MG, and primary membranous nephropathy. - The appointment comes as GlycoEra advances its glyco-engineering platform designed to degrade disease-causing proteins without generalized immunosuppression.

On this page

Overview
Clinical Trials26
Approvals
News1

Back to Organizations